ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	ISRCTN
Last refreshed on:	13 January 2015
Main ID:	ISRCTN09881876
Date of registration:	30/09/2004
Prospective Registration:	No
Primary sponsor:	Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)
Public title:	Optimal timing for Angiotensin Converting Enzyme (ACE) Inhibitor discontinuation in patients undergoing cardiac surgery on cardiopulmonary bypass.
Scientific title:
Date of first enrolment:	01/06/2003
Target sample size:	0
Recruitment status:	Completed
URL:	http://isrctn.com/ISRCTN09881876
Study type:	Interventional
Study design:	Randomised controlled trial (Treatment)
Phase:

Countries of recruitment
United Kingdom

Contacts

Name:
Address:
Telephone:
Email:
Affiliation:

Name:	A A A Ali
Address:	Department of Cardiothoracic Surgery Yorkshire Heart Centre Leeds General Infirmary Great George Street LS1 3EX Leeds United Kingdom
Telephone:	+44 (0)7967 672729
Email:	r&d@leedsth.nhs.uk
Affiliation:

Key inclusion & exclusion criteria

Inclusion criteria: Patients undergoing elective first time coronary artery surgery on the ACE inhibitor Ramipril will be eligible for the study.
Exclusion criteria: Exclusion criteria are redo procedures and poor left ventricular function (Ejection Fraction <30%).

Age minimum:
Age maximum:
Gender: Not Specified

Health Condition(s) or Problem(s) studied

Surgery: Cardiovascular
Surgery
Cardiovascular

Intervention(s)

Patients will be randomised to discontinuing their ACE inhibitor 7 days preoperatively or continuing the medication until the morning of operation.

29/08/2012: Please note that this trial was abandoned before starting.

Primary Outcome(s)

Primary outcome measures are those relating to the presence and treatment of perioperative and postoperative hypotension. Systemic vascular resistance will be measured via Swan-Ganz catheterisation preoperatively and at fixed intervals in the postoperative period. In addition the requirement of vasoconstrictor agents as well as the duration of their use and the total dose administered will be documented.

Secondary Outcome(s)

Not provided at time of registration

Secondary ID(s)

N0436130524

Source(s) of Monetary Support

Leeds Teaching Hospitals NHS Trust (UK)

Secondary Sponsor(s)

Ethics review

Results

Results available:
Date Posted:
Date Completed:
URL:

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.